dexmedetomidine + ketamine + lidocaine (33e451)

This specific opioid-free anesthetic regimen, evaluated by investigator Christine Oryhan, consists of a combination of dexmedetomidine, ketamine, and lidocaine. It was studied in a Phase 3 clinical trial (NCT03143387) as an alternative to traditional opioid-based anesthesia (such as fentanyl) for patients undergoing laparoscopic bariatric surgery. The regimen utilizes a multimodal approach to pain management: dexmedetomidine acts as a selective alpha-2 adrenergic agonist providing sedative and analgesic properties; ketamine serves as an NMDA receptor antagonist to prevent central sensitization; and lidocaine acts as a sodium channel blocker to provide systemic analgesia and anti-inflammatory effects. The primary goal of this combination is to reduce postoperative opioid consumption and associated side effects in the bariatric surgical population.

Other names

Non Opioid AnalgesicsOpioid-free anesthetic regimen